These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 26949899)

  • 21. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
    Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
    J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation.
    Assiri A; Al-Majzoub O; Kanaan AO; Donovan JL; Silva M
    Clin Ther; 2013 Jul; 35(7):967-984.e2. PubMed ID: 23870607
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015.
    Kjerpeseth LJ; Ellekjær H; Selmer R; Ariansen I; Furu K; Skovlund E
    Eur J Clin Pharmacol; 2017 Nov; 73(11):1417-1425. PubMed ID: 28735494
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of apixaban vs. other new oral anticoagulants for the prevention of stroke: an analysis on patients with non-valvular atrial fibrillation in the Greek healthcare setting.
    Athanasakis K; Karampli E; Tsounis D; Bilitou A; Kyriopoulos J
    Clin Drug Investig; 2015 Nov; 35(11):693-705. PubMed ID: 26385756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies.
    Deitelzweig S; Farmer C; Luo X; Vo L; Li X; Hamilton M; Horblyuk R; Ashaye A
    Curr Med Res Opin; 2017 Sep; 33(9):1583-1594. PubMed ID: 28644048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meta-Analysis of Effectiveness and Safety of Oral Anticoagulants in Atrial Fibrillation With Focus on Apixaban.
    Bai Y; Shi XB; Ma CS; Lip GYH
    Am J Cardiol; 2017 Nov; 120(9):1689-1695. PubMed ID: 28844510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.
    Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Vo L
    Curr Med Res Opin; 2017 Sep; 33(9):1595-1604. PubMed ID: 28635338
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation.
    Hernandez I; Zhang Y; Saba S
    Am J Cardiol; 2017 Nov; 120(10):1813-1819. PubMed ID: 28864318
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation.
    Singh SM; Wijeysundera HC
    Curr Cardiol Rep; 2015 Aug; 17(8):61. PubMed ID: 26081245
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting.
    Lin J; Trocio J; Gupta K; Mardekian J; Lingohr-Smith M; Menges B; You M; Nadkarni A
    J Med Econ; 2017 Sep; 20(9):952-961. PubMed ID: 28604139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany.
    Collings SL; Lefèvre C; Johnson ME; Evans D; Hack G; Stynes G; Maguire A
    PLoS One; 2017; 12(10):e0185642. PubMed ID: 29016695
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications.
    Albert NM
    Heart Lung; 2014; 43(1):48-59. PubMed ID: 24373340
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis.
    Savarese G; Giugliano RP; Rosano GM; McMurray J; Magnani G; Filippatos G; Dellegrottaglie S; Lund LH; Trimarco B; Perrone-Filardi P
    JACC Heart Fail; 2016 Nov; 4(11):870-880. PubMed ID: 27614940
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Improvements in oral anticoagulant therapy for atrial fibrillation].
    Briongos Figuero S; García Santos-Gallego C; Badimón JJ
    Med Clin (Barc); 2013 Dec; 141(11):487-93. PubMed ID: 23597953
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Net clinical benefit of oral anticoagulants: a multiple criteria decision analysis.
    Hsu JC; Hsieh CY; Yang YH; Lu CY
    PLoS One; 2015; 10(4):e0124806. PubMed ID: 25897861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation.
    Renda G; Zimarino M; Ricci F; Piccini JP; Ezekowitz MD; Patel MR; Cappato R; Giugliano RP; De Caterina R
    Am J Med; 2016 Oct; 129(10):1117-1123.e2. PubMed ID: 27262782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
    Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
    Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
    Lee SI; Sayers M; Lip GY; Lane DA
    Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights.
    Kumana CR; Cheung BM; Siu DC; Tse HF; Lauder IJ
    Cardiovasc Ther; 2016 Apr; 34(2):100-6. PubMed ID: 26727005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.